Search
Pasithea Therapeutics Corp
KTTAAdd to Watchlist
0.397USD
-0.003-0.75%
Close 10-27 16:00（ET）
13.26MMarket Cap
LossP/E TTM
KTTA Analyst Recommendation Trends
In the current month, KTTA has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KTTA average Analyst price target in the last month is 3.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
Financial Forecasting
Based on analysts' estimates, KTTA EPS is projected to reach -0.210 in FY2026Q3, following reported EPS of -0.164 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.18
-0.45
-0.16
-0.21
-0.25
Actual
-0.79
-0.12
-0.16
--
--
Surprise
-339.85%
+73.80%
-2.68%
--
--
FAQs
How have Pasithea Therapeutics CorpKTTA's recent earnings per share performed?
The market expectation was USD -0.16, while Pasithea Therapeutics CorpKTTA's earnings per share (EPS) for the previous quarter was USD -0.12. EPS for the next quarter is expected at USD -0.21.
What is the analyst rating for Pasithea Therapeutics Corp?
Based on the ratings of Pasithea Therapeutics Corp's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.